11/15/2023 : Alcon’s Third Quarter 2023 Earnings Conference Call
Alcon 2/28/2023 : Alcon’s Fourth Quarter 2022 Earnings Conference Call
Alcon 2/28/2023 : Alcon’s Fourth Quarter 2022 Earnings Conference Call
Alcon 8/16/2023 : Alcon’s Second Quarter 2023 Earnings Conference Call
Alcon 11/15/2023 : Alcon’s Third Quarter 2023 Earnings Conference Call
Alcon 5/10/2023 : Alcon’s First Quarter 2023 Earnings Conference Call
Alcon 1/11/2023 : 41st Annual J.P. Morgan Healthcare Conference
Sandoz News Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
- Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EU
- Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that can drastically affect an individual’s everyday life and requires life-long treatment
- Sandoz is committed to accelerating patient access to potentially life-changing, high-quality treatments, while generating savings for healthcare systems and patients
Basel, July 25, 2022 …
Sandoz News Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
- Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study
- Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic immune-mediated inflammatory diseases
- Sandoz is committed to supporting healthcare professionals to advance patient care and improve access to medicines sustainably and affordably
Basel, July 21, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia